Clinically recognized for its role in reducing liver fat content and improving metabolic markers of non-alcoholic fatty liver disease (NAFLD)
Current evidence suggests that dapagliflozin may elevate the risk of bladder and breast cancers, whereas other SGLT2 inhibitors have not demonstrated such associations [10]
Adapt Peptides supplies retatrutide strictly for laboratory research use
This product is neither a drug, food, nor cosmetic, and must not be misrepresented, misused, or mislabeled as such
This work reflects only the authors views and opinions, neither the Ministry for University and Research nor the European Commission can be considered responsible for them
10.1146/annurev-med-043021-014919 35 JayaramH.KolkoM.FriedmanD